Literature DB >> 27668053

Kyprolis (Carfilzomib) Received New Indications as Combination Therapy for Use in Relapsed and/or Refractory Multiple Myeloma.

Lisa A Raedler.   

Abstract

Entities:  

Year:  2016        PMID： 27668053      PMCID： PMC5013842     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN： 1942-2962


× No keyword cloud information.
  8 in total

1.  Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.

Authors:  April Teitelbaum; Abbie Ba-Mancini; Hui Huang; Henry J Henk
Journal:  Oncologist       Date:  2013-01-08

2.  The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment.

Authors:  Louis P Garrison; Si-Tien Wang; Hui Huang; Abbie Ba-Mancini; Hongliang Shi; Kristina Chen; Caroline Korves; Ravinder Dhawan; Andrew Cakana; Helgi van de Velde; Deyanira Corzo; Mei Sheng Duh
Journal:  Oncologist       Date:  2013-01-08

3.  Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.

Authors:  A Keith Stewart; S Vincent Rajkumar; Meletios A Dimopoulos; Tamás Masszi; Ivan Špička; Albert Oriol; Roman Hájek; Laura Rosiñol; David S Siegel; Georgi G Mihaylov; Vesselina Goranova-Marinova; Péter Rajnics; Aleksandr Suvorov; Ruben Niesvizky; Andrzej J Jakubowiak; Jesus F San-Miguel; Heinz Ludwig; Michael Wang; Vladimír Maisnar; Jiri Minarik; William I Bensinger; Maria-Victoria Mateos; Dina Ben-Yehuda; Vishal Kukreti; Naseem Zojwalla; Margaret E Tonda; Xinqun Yang; Biao Xing; Philippe Moreau; Antonio Palumbo
Journal:  N Engl J Med       Date:  2014-12-06       Impact factor: 91.245

Review 4.  Novel approaches to treatment of double-refractory multiple myeloma.

Authors:  Hans C Lee; Jatin J Shah; Robert Z Orlowski
Journal:  Am Soc Clin Oncol Educ Book       Date:  2013

5.  Improved survival in multiple myeloma and the impact of novel therapies.

Authors:  Shaji K Kumar; S Vincent Rajkumar; Angela Dispenzieri; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; Steven R Zeldenrust; David Dingli; Stephen J Russell; John A Lust; Philip R Greipp; Robert A Kyle; Morie A Gertz
Journal:  Blood       Date:  2007-11-01       Impact factor: 22.113

6.  Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

Authors:  Meletios A Dimopoulos; Philippe Moreau; Antonio Palumbo; Douglas Joshua; Ludek Pour; Roman Hájek; Thierry Facon; Heinz Ludwig; Albert Oriol; Hartmut Goldschmidt; Laura Rosiñol; Jan Straub; Aleksandr Suvorov; Carla Araujo; Elena Rimashevskaya; Tomas Pika; Gianluca Gaidano; Katja Weisel; Vesselina Goranova-Marinova; Anthony Schwarer; Leonard Minuk; Tamás Masszi; Ievgenii Karamanesht; Massimo Offidani; Vania Hungria; Andrew Spencer; Robert Z Orlowski; Heidi H Gillenwater; Nehal Mohamed; Shibao Feng; Wee-Joo Chng
Journal:  Lancet Oncol       Date:  2015-12-05       Impact factor: 41.316

Review 7.  New strategies in the treatment of multiple myeloma.

Authors:  Nikhil C Munshi; Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2013-03-20       Impact factor: 12.531

Review 8.  Multiple myeloma: the bone marrow microenvironment and its relation to treatment.

Authors:  S W Andrews; S Kabrah; J E May; C Donaldson; H R Morse
Journal:  Br J Biomed Sci       Date:  2013       Impact factor: 3.829
  8 in total
  1 in total

Review 1.  Targeting protein quality control pathways in breast cancer.

Authors:  Sara Sannino; Jeffrey L Brodsky
Journal:  BMC Biol       Date:  2017-11-16       Impact factor: 7.431
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.